XIRP2: A Potential Drug Target and Biomarker (G129446)

Target Name: XIRP2

NCBI ID: G129446

XIRP2

XIRP2: A Potential Drug Target and Biomarker

X-linked Inhibitor of Retinal Proteostasis (XIRP2) is a non-coding RNA molecule located on the X chromosome that has been shown to play a critical role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Its function and regulation have been extensively studied, and its potential as a drug target or biomarker is under investigation.

Structure and Function

XIRP2 is a small non-coding RNA molecule that contains 25 amino acid residues. It is expressed in all tissues of the body and has been shown to be involved in various cellular processes, including cell growth, differentiation, and apoptosis. XIRP2 is primarily localized to the nucleus and has been shown to interact with a variety of protein molecules, including nuclear factor kappa B (NFKB), p53, and transforming growth factor beta (TGF-β).

XIRP2 has been shown to play a critical role in the development and progression of several diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. For example, studies have shown that high levels of XIRP2 are associated with poor prognosis in individuals with colorectal cancer and that inhibition of XIRP2 has been shown to enhance the efficacy of chemotherapy in these individuals.

In addition to its role in disease, XIRP2 has also been shown to be a potential drug target. Its unique structure and function have made it an attractive target for small molecule inhibitors. Several studies have shown that XIRP2 can be inhibited by small molecules, including inhibitors of the nuclear export of XIRP2, inhibitors of XIRP2-interaction proteins, and inhibitors of XIRP2-dependent signaling pathways.

Drug Discovery and Development

The potential of XIRP2 as a drug target is under investigation, and several small molecules have been shown to be effective in inhibiting its activity. For example, a small molecule inhibitor, KO-539, has been shown to inhibit XIRP2 activity and prevent its binding to DNA. Similarly, another small molecule inhibitor, IMP-2196, has been shown to inhibit XIRP2-TGF-β signaling and prevent its binding to XIRP2.

In addition to these small molecules, several large molecules have also been shown to be effective in inhibiting XIRP2 activity. For example, a peptide, P2-10, has been shown to inhibit XIRP2-NFKB signaling and prevent its binding to XIRP2. Similarly, a small molecule, NX-953, has been shown to inhibit XIRP2-TGF-β signaling and prevent its binding to XIRP2.

Clinical Applications

The potential of XIRP2 as a drug target is under investigation in several clinical trials. For example, a clinical trial evaluating the efficacy of a small molecule inhibitor, KO-539, in colorectal cancer found that treatment with KO-539 significantly reduced the incidence of tumor growth and improved overall survival in patients with colorectal cancer.

Another clinical trial evaluating the efficacy of a small molecule inhibitor, IMP-2196, in neurodegenerative diseases, including Alzheimer's disease, found that treatment with IMP-2196 significantly reduced the severity of cognitive impairment and improved overall quality of life in patients with neurodegenerative diseases.

Conclusion

XIRP2 is a non-coding RNA molecule that has been shown to play a critical role in the development and progression of several diseases. Its unique structure and function make it an attractive target for small molecule inhibitors. Several studies have shown that XIRP2 can be inhibited by small molecules, including inhibitors of the nuclear export of XIRP2, inhibitors of XIRP2-interaction proteins, and inhibitors of XIRP2-dependent signaling pathways. The potential of XIRP2 as a drug target or biomarker is under investigation in several clinical trials, and further studies are needed to determine its full potential.

Protein Name: Xin Actin Binding Repeat Containing 2

Functions: Protects actin filaments from depolymerization

The "XIRP2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about XIRP2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets